Literature DB >> 6384652

Corynebacterium group JK peritonitis in patients on continuous ambulatory peritoneal dialysis.

M Altwegg, K Záruba, A von Graevenitz.   

Abstract

Corynebacterium group JK is described as the aetiologic agent of a second episode of peritonitis which occurred after a period of antibiotic treatment for likely endogenous peritonitis. Inclusion of vancomycin is suggested for treatment of continuous ambulatory peritoneal dialysis (CAPD) peritonitis in patients colonized by these multiresistant bacteria.

Entities:  

Mesh：

Year:  1984        PMID： 6384652     DOI： 10.1007/bf01721780

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  11 in total

1.  Characterization and identification of 95 diphtheroid (group JK) cultures isolated from clinical specimens.

Authors:  P S Riley; D G Hollis; G B Utter; R E Weaver; C N Baker
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

2.  Clinical significance of resistant corynebacteria group JK.

Authors:  H Finger; C H Wirsing von Koenig; S Wichmann; E Becker-Boost; H J Drechsler
Journal:  Lancet       Date:  1983-03-05       Impact factor: 79.321

3.  Early diagnosis of peritoneal infection during continuous ambulatory peritoneal dialysis by the dialysate-digest medium-tube method.

Authors:  K Záruba; M Oliveri
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

Review 4.  Microbiologic aspects of chronic ambulatory peritoneal dialysis.

Authors:  S I Vas
Journal:  Kidney Int       Date:  1983-01       Impact factor: 10.612

5.  Prophylaxis of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) by a simple microbiological patient self-check.

Authors:  K Záruba; M Oliveri
Journal:  Proc Eur Dial Transplant Assoc       Date:  1981

6.  Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.

Authors:  R Gokal; J M Ramos; D M Francis; R E Ferner; T H Goodship; G Proud; A J Bint; M K Ward; D N Kerr
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

7.  A new technique of continuous ambulatory peritoneal dialysis (CAPD): double-bag system for freedom to the patient and significant reduction of peritonitis.

Authors:  G Bazzato; S Landini; U Coli; S Lucatello; A Fracasso; M Moracchiello
Journal:  Clin Nephrol       Date:  1980-06       Impact factor: 0.975

8.  Group JK corynebacterium peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  D Pierard; S Lauwers; M C Mouton; J Sennesael; D Verbeelen
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

9.  [Septicemia by Corynebacterium group JK in a polytraumatized patient (author's transl)].

Authors:  C H Wirsing von König; H J Drechsler; S Wichmann; H Finger
Journal:  Klin Wochenschr       Date:  1982-03-01

10.  The emergence of coryneform bacteria as a cause of nosocomial infections in compromised hosts.

Authors:  V M Young; W F Meyers; M R Moody; S C Schimpff
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965
View more
  4 in total

1.  Biochemical and cultural characteristics of "JK" coryneforms.

Authors:  R Bayston; J Higgins
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

2.  Production of extracellular slime by coryneforms colonizing hydrocephalus shunts.

Authors:  R Bayston; C Compton; K Richards
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

3.  Acute peritonitis due to Corynebacterium ulcerans in a patient receiving continuous ambulatory peritoneal dialysis: a case report and literature review.

Authors:  Yukihiro Kimura; Yasuko Watanabe; Norihiro Suga; Natsuko Suzuki; Kunihiro Maeda; Keisuke Suzuki; Wataru Kitagawa; Naoto Miura; Hiroyuki Morita; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2010-09-14       Impact factor: 2.801

Review 4.  Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis.

Authors:  A von Graevenitz; D Amsterdam
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.